About Alnylam
Alnylam is a company based in Cambridge (United States) founded in 2002 by Paul Schimmel, Phillip Sharp, and John Clarke.. Alnylam has raised $17 million across 7 funding rounds from investors including Blackstone, Arch Venture Partners and Atlas Venture. The company has 2,230 employees as of December 31, 2024. Alnylam has completed 2 acquisitions, including Nucleonics and Sirna Therapeutics. Alnylam operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, ATAI, Insitro and Ultragenyx, among others.
- Headquarter Cambridge, United States
- Employees 2230 as on 31 Dec, 2024
- Founders Paul Schimmel, Phillip Sharp, John Clarke
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alnylam Pharmaceuticals, Inc.
-
Annual Revenue
$2.25 B22.97as on Dec 31, 2024
-
Net Profit
$-278.16 M36.82as on Dec 31, 2024
-
EBITDA
$-120.22 M47.3as on Dec 31, 2024
-
Total Equity Funding
$17 M (USD)
in 7 rounds
-
Latest Funding Round
$150 M (USD), Post-IPO
Aug 17, 2020
-
Investors
Blackstone
& 7 more
-
Employee Count
2230
as on Dec 31, 2024
-
Investments & Acquisitions
Nucleonics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Alnylam
Alnylam is a publicly listed company on the NASDAQ with ticker symbol ALNY in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Unlock access to complete
Unlock access to complete
Software Development Team
142 people
Leadership Team
113 people
Senior Team
52 people
Finance and Accounting
36 people
Operations Team
31 people
Legal and Compliance
30 people
Human Resources and Administration
28 people
Principal Team
27 people
Unlock access to complete
Funding Insights of Alnylam
Alnylam has successfully raised a total of $17M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $150 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $150.0M
-
First Round
First Round
(01 Aug 2002)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2020 | Amount | Post-IPO - Alnylam | Valuation |
investors |
|
| Apr, 2020 | Amount | Post-IPO - Alnylam | Valuation |
investors |
|
| Nov, 2017 | Amount | Post-IPO - Alnylam | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Alnylam
Alnylam has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, Arch Venture Partners and Atlas Venture. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment management is provided across multiple asset classes.
|
Founded Year | Domain | Location | |
|
Early stage venture capital firm investing in US
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on life science companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Alnylam
Alnylam has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Nucleonics and Sirna Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
RNAi therapeutics for viral diseases including Hepatitis-B were developed.
|
2001 | ||||
|
Develops RNAi-based therapies
|
1992 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Alnylam
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alnylam Comparisons
Competitors of Alnylam
Alnylam operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, ATAI, Insitro and Ultragenyx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| domain | founded_year | HQ Location |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alnylam
Frequently Asked Questions about Alnylam
When was Alnylam founded?
Alnylam was founded in 2002.
Where is Alnylam located?
Alnylam is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Alnylam?
John Maraganore is the current CEO of Alnylam.
Is Alnylam a funded company?
Alnylam is a funded company, having raised a total of $17M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $700M, raised on Aug 01, 2002.
How many employees does Alnylam have?
As of Dec 31, 2024, the latest employee count at Alnylam is 2,230.
What is the annual revenue of Alnylam?
Annual revenue of Alnylam is $2.25B as on Dec 31, 2024.
What does Alnylam do?
Alnylam was founded in 2002 and is headquartered in Cambridge, United States. RNA interference therapeutics are developed for genetic and other disorders within the biotechnology sector. The pipeline encompasses treatments for hereditary ATTR amyloidosis, acute hepatic porphyria, and hypercholesterolemia. Further development targets cardiometabolic conditions, infectious diseases, central nervous system disorders, and ocular diseases. Operations emphasize research and drug advancement in these areas.
Who are the top competitors of Alnylam?
Alnylam's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Is Alnylam publicly traded?
Yes, Alnylam is publicly traded on NASDAQ under the ticker symbol ALNY.
How many acquisitions has Alnylam made?
Alnylam has made 2 acquisitions, including Nucleonics, and Sirna Therapeutics.
Who are Alnylam's investors?
Alnylam has 8 investors. Key investors include Blackstone, Arch Venture Partners, Atlas Venture, Genzyme, and Abingworth.
What is Alnylam's ticker symbol?
The ticker symbol of Alnylam is ALNY on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.